Related Experiment Video
Updated: Jul 24, 2025
00:04
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
10.7K
Treatment Retention Rates of 3-monthly Paliperidone Palmitate and Risk Factors Associated with Discontinuation: A
Chien-Heng Lin1,2, Huang-Li Lin3,4, Chih-Lin Chiang5,6
1Department of Psychiatry, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu Country, Taiwan.
Summary
Real-world data show that prior paliperidone palmitate (PP1M) duration and adequate initiation of 3-monthly paliperidone palmitate (PP3M) improve treatment retention. Better PP3M retention reduces psychiatric hospitalization risk.
Area of Science:
- Psychiatry
- Pharmacology
- Real-world evidence
Background:
- Limited real-world data exist on 3-monthly paliperidone palmitate (PP3M) treatment retention and influencing factors.
- Understanding these factors is crucial for optimizing long-acting injectable antipsychotic therapy in schizophrenia.
Purpose of the Study:
- To investigate real-world treatment retention rates for 3-monthly paliperidone palmitate (PP3M) in adult schizophrenia patients.
- To identify key factors associated with PP3M treatment retention and subsequent psychiatric hospitalization.
Main Methods:
- Retrospective nationwide cohort study using Taiwan's National Health Insurance Research Database (October 2017–December 2019).
- Adult schizophrenia patients initiated on PP3M were analyzed for time to discontinuation, time to psychiatric hospitalization, and next-dose adherence.
- Covariates included prior paliperidone palmitate 1-monthly (PP1M) duration and adequacy of PP3M initiation.
Main Results:
- 2-year PP3M treatment retention rates were 52.5%.
- High adherence (86.4%-90.0%) to subsequent doses was observed among completers.
- Adequate PP3M initiation and prior PP1M duration >180 days were linked to better retention.
- Inadequate initiation and shorter PP1M duration increased discontinuation risk.
- First-year adherence to PP3M correlated with a lower risk of psychiatric hospitalization at 2 years.
Conclusions:
- Prior PP1M treatment duration and adequate PP3M initiation are critical determinants of PP3M treatment retention.
- Improved PP3M treatment retention is associated with a reduced risk of psychiatric hospitalization in schizophrenia patients.
Keywords:
Long-acting injectable antipsychoticPaliperidone palmitatePsychiatric hospitalizationReal-worldSchizophreniaTreatment retentionMore Related Videos
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
170
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
170
01:28Psychosis and Antipsychotic Drugs: Overview
336
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
336
01:28Drug Therapy
73
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
73
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
206
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
206
01:24Parkinson's Disease: Treatment
302
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
302
01:12Analysis of Population Pharmacokinetic Data
299
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
299